Detalhe da pesquisa
1.
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
Vaccine
; 41(50): 7548-7559, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37977942
2.
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
Vaccine
; 38(19): 3560-3569, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209248
3.
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
Pediatr Infect Dis J
; 39(10): 955-960, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852352
4.
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.
Hum Vaccin Immunother
; 16(6): 1292-1298, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209015
5.
Supporting clinical teachers - a review of the literature.
Aust Fam Physician
; 37(4): 247-9, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18398523
6.
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Pediatr Infect Dis J
; 35(6): 673-82, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26974889
7.
Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
Vaccine
; 33(18): 2175-82, 2015 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25744224
8.
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Pediatr Infect Dis J
; 31(4): e59-65, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22418661
9.
PCR analysis.
Aust Fam Physician
; 33(9): 679, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15487354